Virtus ETF Advisers LLC Kezar Life Sciences, Inc. Transaction History

Virtus ETF Advisers LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$3.13 - $7.31 $16,873 - $39,408	-5,391 Reduced 27.75%	14,036 $43,000
Q4 2022 Feb 14, 2023	SELL	$6.39 - $8.8 $17,310 - $23,839	-2,709 Reduced 12.24%	19,427 $136,000
Q3 2022 Nov 14, 2022	BUY	$7.99 - $10.75 $1,326 - $1,784	166 Added 0.76%	22,136 $191,000
Q2 2022 Aug 12, 2022	BUY	$4.58 - $17.13 $43,175 - $161,484	9,427 Added 75.16%	21,970 $182,000
Q1 2022 May 16, 2022	SELL	$12.3 - $18.33 $9,175 - $13,674	-746 Reduced 5.61%	12,543 $208,000
Q4 2021 Feb 14, 2022	BUY	$7.44 - $16.72 $98,870 - $222,192	13,289 New	13,289 $222,000
Q2 2021 Aug 10, 2021	SELL	$4.93 - $6.46 $267,763 - $350,861	-54,313 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$5.24 - $6.99 $5,056 - $6,745	965 Added 1.81%	54,313 $324,000
Q4 2020 Feb 12, 2021	SELL	$4.77 - $6.58 $49,326 - $68,043	-10,341 Reduced 16.24%	53,348 $278,000
Q3 2020 Nov 13, 2020	SELL	$4.36 - $5.5 $37,884 - $47,789	-8,689 Reduced 12.01%	63,689 $308,000
Q2 2020 Aug 05, 2020	BUY	$3.6 - $7.75 $260,560 - $560,929	72,378 New	72,378 $375,000

38.4M

13.8K

600

Ticker KZR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,369,504
Market Cap $446M
Description
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical tria...

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

Stay updated on Virtus ETF Advisers LLC with notifications on news.